SCHEMBL6204492

SCHEMBL6204492

CC(=O)Nc1cccc(-c2ccc(OC(=O)O)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
CYP17A1 P05093 1/20 0.54
CYP11B1 P15538 1/20 0.54
CYP11B2 P19099 1/20 0.54
HSD17B1 P14061 1/20 0.53
HSD17B2 P37059 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
FYN P06241 1/20 0.53
MGLL Q99685 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TSHR P16473 1/20 0.51
ADAMTS4 O75173 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3786463 0.84 NQO2 (0.73) NQO2CYP17A1CYP11B1CYP11B2HSD17B1
SCHEMBL8577619 0.82 SMN1; SMN2 (0.70) NQO2CYP17A1CYP11B1CYP11B2HSD17B1
SCHEMBL1749196 0.80 MEN1 (0.59) NQO2CYP17A1CYP11B1CYP11B2HSD17B1
SCHEMBL3675252 0.80 RAB9A (0.65) LMNACYP17A1CYP11B1CYP11B2MGLL
SCHEMBL12999591 0.80 NPC1 (0.69) NQO2LMNACYP17A1CYP11B1CYP11B2
SCHEMBL27816274 0.79 KMT2A (0.78) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL6251220 0.79 LMNA (0.45) LMNAGAAADORA3MGLLMEN1
SCHEMBL4654909 0.78 ALDH1A1 (0.67) NQO2CYP17A1CYP11B1CYP11B2HSD17B1
SCHEMBL969807 0.78 RAB9A (0.65) NQO2LMNACYP17A1CYP11B1CYP11B2
SCHEMBL14384612 0.78 CNR1 (0.71) CYP17A1CYP11B1CYP11B2HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1597228-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-23 EP disclosed
WO-2004072025-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 WO disclosed